Brain

Tiziana Life Sciences to Pursue Development of Intranasal Foralumab for the Treatment of Long COVID

Long COVID remains a high unmet need causing a myriad of complications for patients and costing the U.S. healthcare system…

1 year ago

Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress

BRISBANE, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing…

1 year ago

Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R. Bryan Miller Symposium

Dr. Redkar to discuss importance of HGF/cMET pathway, which can play critical role in origin of several cancersFOSTER CITY, Calif.,…

1 year ago

Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference

Eight Abstracts Demonstrate Progress of Prelude’s Differentiated PipelineWILMINGTON, Del., April 11, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD),…

1 year ago

electroCore Announces Remittance of Annual License Fee from Teijin for Certain Exclusive Rights in Japan

ROCKAWAY, N.J., April 11, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness…

1 year ago

Impel Pharmaceuticals to Present Data on Trudhesa® Nasal Spray for Treatment of Acute Migraine at 2023 American Academy of Neurology Annual Meeting

Highlights Include Multiple Presentations Addressing Safety and Efficacy of TrudhesaSEATTLE, April 11, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL),…

1 year ago

Cerevance to Present at the Needham Healthcare Conference

BOSTON, April 10, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous…

1 year ago

Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference

NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a  biopharmaceutical company committed to developing medicines…

1 year ago

Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting

Data show that DNL343 is generally well-tolerated at doses that demonstrate robust inhibition of biomarkers associated with the integrated stress…

1 year ago

ProMIS Neurosciences Announces Submission of Investigational New Drug (IND) Application for Lead Antibody PMN310

TORONTO, Ontario and CAMBRIDGE, Massachusetts, April 10, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology…

1 year ago